Trial Profile
STOP-CA (Statins TO Prevent the Cardiotoxicity From Anthracyclines)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Dec 2023
Price :
$35
*
At a glance
- Drugs Atorvastatin (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- Acronyms STOP-CA
- 29 Nov 2023 Status changed from active, no longer recruiting to completed.
- 08 Aug 2023 Primary endpoint has been met. (Left ventricular Ejection Fraction (LVEF))
- 08 Aug 2023 Results published in the JAMA: the Journal of the American Medical Association